KGbio
Indriani Saraswati has experience in business development and licensing in the pharmaceutical industry, with a focus on biologics and biosimilar products in oncology and other high-specialty therapeutic areas. Indriani has also held various roles in export business management and product development, showcasing their diverse skills in marketing and strategy planning. Their educational background includes a Bachelor of Pharmacy and Apothecary Profession degrees from Universitas Padjadjaran.
KGbio
KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).